Biopharmaceutical

Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement and Mutual Release

Retrieved on: 
Friday, December 1, 2023
Biotechnology, Other Health, Health, Pharmaceutical, Health Technology, Stock, CRG, Biopharmaceutical, Loan agreement, Judgement, Forgiveness, OTC, Security (finance)

On August 30, 2022, a judgment was entered against Navidea, plus post-judgment interest, and Navidea appealed.

Key Points: 
  • On August 30, 2022, a judgment was entered against Navidea, plus post-judgment interest, and Navidea appealed.
  • The binding settlement agreement and mutual release resolves the judgment and settles all litigation between Navidea and CRG, including the pending appeal.
  • This settlement agreement and mutual release also positions the Company to continue driving the organization forward and advance its innovative technology to market, following the Navidea’s Fix, Fund, Propel approach.
  • “We are pleased with the result and timing of this settlement,” said Craig A. Dais, Navidea’s Chief Financial Officer.

AstraZeneca launches Evinova, a health-tech business to accelerate innovation across the life sciences sector, the delivery of clinical trials and better health outcomes

Retrieved on: 
Monday, November 20, 2023
Oncology, Health, Infectious Diseases, Health Technology, Clinical Trials, Pharmaceutical, Biotechnology, Medicine, Electronic health record, Carbon, Woman, Data science, Software, GDP, OECD, Hardware, Collection, Social media, Investment, Clinical trial, Long-term care, Patient, P, Biopharmaceutical, Immunology, Recruitment, Algorithm, Region, Machine learning, Therapy, Digital, Component, Digital technology, Accenture, Cancer, Parexel, McKinsey & Company, Amazon Web Services, Commiskey, Indiana, MHealth, AI, ChromeOS, Telecare, Metabolism, Public, Drug development, Pharmaceutical industry, Medical imaging, Online shopping, Risk management, Health care, Fine chemical, AstraZeneca, Mridha Bonam Mridha, Nature Medicine

The technologies have already been used in the successful delivery of multiple AstraZeneca-sponsored clinical trials in over 40 countries.

Key Points: 
  • The technologies have already been used in the successful delivery of multiple AstraZeneca-sponsored clinical trials in over 40 countries.
  • The suite includes:
    Evinova unified trial solution: A global GxP-validated solution for patients, clinical trial site staff and clinical trial sponsor staff to improve delivery of clinical trials.
  • It enables the delivery of traditional, hybrid and decentralised clinical trials while enhancing the patient experience.
  • Evinova is a health-tech business, accelerating the delivery of better health outcomes by propelling the life sciences sector forward in digital health, from the inside.

Titans Gather, Future Embarks: The GenScript Biotech Global Forum coinciding with the 2024 J.P. Morgan Healthcare Conference in San Francisco to Convene 20+ KOLs, Exploring Disruptive Transformations and Infinite Opportunities in GCT

Retrieved on: 
Thursday, December 14, 2023
Drug development, Eli Lilly and Company, Assistant, CBO, Partner (business rank), Senior, GenScript Biotech, Intellia Therapeutics, Gene editing, Entrepreneurship, Therapy, ARCH Venture Partners, Neogene, Biopharmaceutical, Flagship Pioneering, CSO, Value of life, FDA, Science, GCT, Forum, CRISPR, Speech, Life, Process, Medical device, Pharmaceutical industry, Nightclub, Fine chemical, Research

NANJING, China, Dec. 14, 2023 /PRNewswire/ -- Technological advancements continuously empower the life sciences. Gene and cell therapy (GCT), as breakthrough treatments, are turning the once-unreachable dream of curing many diseases into reality. Recently, the world's first CRISPR-Cas9 gene-editing therapy received market approval, marking another significant milestone in human biomedical progress.

Key Points: 
  • Gene and cell therapy (GCT), as breakthrough treatments, are turning the once-unreachable dream of curing many diseases into reality.
  • On January 10, 2024, the GenScript Biotech Global Forum will once again kick off in San Francisco.
  • Peter Marks, director of FDA's Center for Biologics Evaluation and Research (CBER) will make his keynote speech at the GenScript Biotech Global Forum.
  • On January 10, 2024, we cordially invite you to join us in San Francisco for the GenScript Biotech Global Forum.

Insect Cell Culture Market Size to Grow USD 3.74 Billion by 2029 at a CAGR of 8.3% | Valuates Reports

Retrieved on: 
Thursday, November 30, 2023
Medicine, Attention, Glycosylation, Category, Research, Virus-like particle, Biology, Biotechnology, Protein, Insect cell culture, Serum, New Classics Media, Growth, Vaccine, USD, Biopharmaceutical, Cytogenetics, A-DNA, Transfection, Fine chemical

The global Insect Cell Culture market was valued at USD 2.31 Billion in 2022 and is anticipated to reach USD 3.74 Billion by 2029, witnessing a CAGR of 8.3% during the forecast period 2023-2029.

Key Points: 
  • The global Insect Cell Culture market was valued at USD 2.31 Billion in 2022 and is anticipated to reach USD 3.74 Billion by 2029, witnessing a CAGR of 8.3% during the forecast period 2023-2029.
  • Claim Your Free Sample Now: https://reports.valuates.com/request/sample/QYRE-Auto-35F1907/Global_Ins...
    Major Factors Driving the Growth of Insect Cell Culture Market:
    The market for insect cell culture is expanding significantly due to its many uses in biotechnology.
  • The market for insect cell culture is developing due to its growing use in the manufacturing of vaccines.
  • The market for insect cell culture is expanding as a result of increased expenditures made in the biotechnology industry worldwide.

Insect Cell Culture Market Size to Grow USD 3.74 Billion by 2029 at a CAGR of 8.3% | Valuates Reports

Retrieved on: 
Thursday, November 30, 2023
Medicine, Attention, Glycosylation, Category, Research, Virus-like particle, Biology, Biotechnology, Protein, Insect cell culture, Serum, New Classics Media, Growth, Vaccine, USD, Biopharmaceutical, Cytogenetics, A-DNA, Transfection, Fine chemical

The global Insect Cell Culture market was valued at USD 2.31 Billion in 2022 and is anticipated to reach USD 3.74 Billion by 2029, witnessing a CAGR of 8.3% during the forecast period 2023-2029.

Key Points: 
  • The global Insect Cell Culture market was valued at USD 2.31 Billion in 2022 and is anticipated to reach USD 3.74 Billion by 2029, witnessing a CAGR of 8.3% during the forecast period 2023-2029.
  • Claim Your Free Sample Now: https://reports.valuates.com/request/sample/QYRE-Auto-35F1907/Global_Ins...
    Major Factors Driving the Growth of Insect Cell Culture Market:
    The market for insect cell culture is expanding significantly due to its many uses in biotechnology.
  • The market for insect cell culture is developing due to its growing use in the manufacturing of vaccines.
  • The market for insect cell culture is expanding as a result of increased expenditures made in the biotechnology industry worldwide.

John Booth to Retire as CEO of Spineology Inc.

Retrieved on: 
Thursday, November 9, 2023
Medical Devices, Health, Hospitals, Surgery, General Health, Biotechnology, ATEC, BBA, Spine, Duke University, Fuqua School, George Washington University, Snider, MBA, NuVasive, Triple accreditation, Growth, Inc., Business, Information system, Biopharmaceutical, Management, Vertebral column, Marketing

Spineology Inc. (“Spineology” or the “Company”), the leader in ultra-minimally invasive spine surgery, announced today that John Booth will retire from his role as Chief Executive Officer of Spineology, effective November 10, 2023.

Key Points: 
  • Spineology Inc. (“Spineology” or the “Company”), the leader in ultra-minimally invasive spine surgery, announced today that John Booth will retire from his role as Chief Executive Officer of Spineology, effective November 10, 2023.
  • Mr. Booth will remain with Spineology through 2024, serving in an advisory role to facilitate a smooth transition.
  • Mr. Booth will also resign from the Board of Directors, and the Board has nominated Mr. Snider as a Director.
  • Snider joins Spineology with nearly twenty years of progressive leadership experience in the medical device industry.

Eccogene Enters Exclusive License Agreement With AstraZeneca to Develop and Commercialize Small Molecule GLP-1 Receptor Agonist ECC5004 for Cardiometabolic Diseases

Retrieved on: 
Thursday, November 9, 2023
Biopharmaceutical, Type, AstraZeneca, Patient, Obesity, Health insurance, Pharmaceutical industry

BOSTON and SHANGHAI, Nov. 9, 2023 /PRNewswire/ -- Eccogene announced today that it entered into an exclusive license agreement with AstraZeneca under which AstraZeneca will develop and commercialize Eccogene's small molecule GLP-1 receptor agonist (GLP-1RA) ECC5004 for the potential treatment of obesity, type-2 diabetes and other comorbidities.

Key Points: 
  • AstraZeneca will receive an exclusive license to develop and commercialize ECC5004 in all territories except China.
  • BOSTON and SHANGHAI, Nov. 9, 2023 /PRNewswire/ -- Eccogene announced today that it entered into an exclusive license agreement with AstraZeneca under which AstraZeneca will develop and commercialize Eccogene's small molecule GLP-1 receptor agonist (GLP-1RA) ECC5004 for the potential treatment of obesity, type-2 diabetes and other comorbidities.
  • "GLP-1RA represents a very important class of drugs for multiple cardiometabolic diseases; currently there is no approved orally available small molecule GLP-1RA.
  • In exchange, AstraZeneca will receive exclusive rights to develop and commercialize Eccogene's ECC5004 small molecule GLP-1RA for any indication in all territories except China.

Eccogene Enters Exclusive License Agreement With AstraZeneca to Develop and Commercialize Small Molecule GLP-1 Receptor Agonist ECC5004 for Cardiometabolic Diseases

Retrieved on: 
Thursday, November 9, 2023
Biopharmaceutical, Type, AstraZeneca, Patient, Obesity, Health insurance, Pharmaceutical industry

BOSTON and SHANGHAI, Nov. 9, 2023 /PRNewswire/ -- Eccogene announced today that it entered into an exclusive license agreement with AstraZeneca under which AstraZeneca will develop and commercialize Eccogene's small molecule GLP-1 receptor agonist (GLP-1RA) ECC5004 for the potential treatment of obesity, type-2 diabetes and other comorbidities.

Key Points: 
  • AstraZeneca will receive an exclusive license to develop and commercialize ECC5004 in all territories except China.
  • BOSTON and SHANGHAI, Nov. 9, 2023 /PRNewswire/ -- Eccogene announced today that it entered into an exclusive license agreement with AstraZeneca under which AstraZeneca will develop and commercialize Eccogene's small molecule GLP-1 receptor agonist (GLP-1RA) ECC5004 for the potential treatment of obesity, type-2 diabetes and other comorbidities.
  • "GLP-1RA represents a very important class of drugs for multiple cardiometabolic diseases; currently there is no approved orally available small molecule GLP-1RA.
  • In exchange, AstraZeneca will receive exclusive rights to develop and commercialize Eccogene's ECC5004 small molecule GLP-1RA for any indication in all territories except China.

Stevanato Group Reports Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, October 31, 2023
Science, Biotechnology, Research, Pharmaceutical, Health, Engineering, Health Technology, Manufacturing, Ageing, Biomedical Advanced Research and Development Authority, NYSE, PIN, Public expenditure, EBITDA, Marex (British company), BARDA, Development, Segment, Growth, Biopharmaceutical, EPS, Medicine, Webcast, Messenger, Depreciation, DCS, Investment, COVID-19, Pharmaceutical industry, Video game, Fine chemical, Fertilizer

Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the third quarter of 2023.

Key Points: 
  • Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the third quarter of 2023.
  • Adjusted EBITDA margin increased 70 basis points to 27.5% in the third quarter of 2023, compared with the third quarter of 2022.
  • This led to gross profit margin of 32.7% and operating profit margin of 21.2% for the third quarter of 2023.
  • The Company will host a conference call and webcast at 8:30 a.m. (ET) on Tuesday, October 31, 2023 to discuss financial results.

SparX Biopharmaceutical Announces FDA Greenlight for IND Application of SPX-303, A First-In-Human anti-LILRB2/PD-L1 Antibody Drug

Retrieved on: 
Monday, October 30, 2023
FDA, PD-L1, Trial of the century, Sparx, IND, Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Biopharmaceutical, LILRB2, Neoplasm, Immune system, Cancer, Safety, Patient, Pharmaceutical industry, Vaccine

CHICAGO, Oct. 30, 2023 /PRNewswire/ -- Signifying a monumental step forward in the domain of powered antibody therapies, SparX Biopharmaceutical Corp. proudly announces that its Investigational New Drug (IND) application for SPX-303, a First-in-Class anti-LILRB2/PD-L1 bispecific antibody drug candidate, has been greenlighted by the U.S. Food and Drug Administration (FDA).

Key Points: 
  • CHICAGO, Oct. 30, 2023 /PRNewswire/ -- Signifying a monumental step forward in the domain of powered antibody therapies, SparX Biopharmaceutical Corp. proudly announces that its Investigational New Drug (IND) application for SPX-303, a First-in-Class anti-LILRB2/PD-L1 bispecific antibody drug candidate, has been greenlighted by the U.S. Food and Drug Administration (FDA).
  • This approval propels SparX's enduring commitment to deliver groundbreaking solutions to patients grappling with advanced or refractory solid tumors.
  • Dr. Gui-Dong Zhu, Chief Executive Officer of SparX Biopharmaceutical, shared his exhilaration: "Receiving the FDA's green light on our IND application is a seminal moment in our ongoing journey to redefine the paradigms of cancer treatment.
  • Developed by SparX, SPX-303 is a First-in-Its Class bispecific antibody therapy, ingeniously engineered to engage two cardinal immune checkpoint proteins, LILRB2 and PD-L1, simultaneously.